Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Gene Therapy for Age-related Macular Degeneration market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Gene Therapy for Age-related Macular Degenerationmarket, defines the market attractiveness level of Gene Therapy for Age-related Macular Degeneration market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Gene Therapy for Age-related Macular Degeneration industry, describes the types of Gene Therapy for Age-related Macular Degeneration market, the applications of major players and the market size, and deeply analyzes the current situation of the global Gene Therapy for Age-related Macular Degeneration market and the development prospects and opportunities of Gene Therapy for Age-related Macular Degeneration industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Gene Therapy for Age-related Macular Degeneration market in Chapter 13.
By Player:
REGENXBIO
RetroSense Therapeutics
AGTC
By Type:
Subretinal
Intravitreal
Unspecified
By End-User:
Monotherapy
Combination Therapy
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Gene Therapy for Age-related Macular Degeneration Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Gene Therapy for Age-related Macular Degeneration Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Gene Therapy for Age-related Macular Degeneration Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Gene Therapy for Age-related Macular Degeneration Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Gene Therapy for Age-related Macular Degeneration Market Analysis and Outlook to 2022
-
7.1 Global Gene Therapy for Age-related Macular Degeneration Consumption (2017-2022)
-
7.2 United States Gene Therapy for Age-related Macular Degeneration Consumption (2017-2022)
-
7.3 Europe Gene Therapy for Age-related Macular Degeneration Consumption (2017-2022)
-
7.4 China Gene Therapy for Age-related Macular Degeneration Consumption (2017-2022)
-
7.5 Japan Gene Therapy for Age-related Macular Degeneration Consumption (2017-2022)
-
7.6 India Gene Therapy for Age-related Macular Degeneration Consumption (2017-2022)
-
7.7 South Korea Gene Therapy for Age-related Macular Degeneration Consumption (2017-2022)
8 Region and Country-wise Gene Therapy for Age-related Macular Degeneration Market Analysis and Outlook to 2028
-
8.1 Global Gene Therapy for Age-related Macular Degeneration Consumption Forecast (2022-2028)
-
8.2 United States Gene Therapy for Age-related Macular Degeneration Consumption Forecast (2022-2028)
-
8.3 Europe Gene Therapy for Age-related Macular Degeneration Consumption Forecast (2022-2028)
-
8.4 China Gene Therapy for Age-related Macular Degeneration Consumption Forecast (2022-2028)
-
8.5 Japan Gene Therapy for Age-related Macular Degeneration Consumption Forecast (2022-2028)
-
8.6 India Gene Therapy for Age-related Macular Degeneration Consumption Forecast (2022-2028)
-
8.7 South Korea Gene Therapy for Age-related Macular Degeneration Consumption Forecast (2022-2028)
9 Global Gene Therapy for Age-related Macular Degeneration Market Outlook by Types and Applications to 2022
-
9.1 Global Gene Therapy for Age-related Macular Degeneration Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Subretinal Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Intravitreal Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Unspecified Consumption and Growth Rate (2017-2022)
-
9.2 Global Gene Therapy for Age-related Macular Degeneration Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Monotherapy Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Combination Therapy Consumption and Growth Rate (2017-2022)
10 Global Gene Therapy for Age-related Macular Degeneration Market Outlook by Types and Applications to 2028
-
10.1 Global Gene Therapy for Age-related Macular Degeneration Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Subretinal Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Intravitreal Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Unspecified Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Gene Therapy for Age-related Macular Degeneration Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Monotherapy Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Combination Therapy Consumption Forecast and Growth Rate (2022-2028)
11 Global Gene Therapy for Age-related Macular Degeneration Import and Export Analysis (Top 5 Countries)
-
11.1 Global Gene Therapy for Age-related Macular Degeneration Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Gene Therapy for Age-related Macular Degeneration Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Gene Therapy for Age-related Macular Degeneration Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Gene Therapy for Age-related Macular Degeneration Market Competitive Analysis
-
14.1 REGENXBIO
-
14.1.1 REGENXBIO Company Details
-
14.1.2 REGENXBIO Gene Therapy for Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Product and Service
-
14.2 RetroSense Therapeutics
-
14.2.1 RetroSense Therapeutics Company Details
-
14.2.2 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Product and Service
-
14.3 AGTC
-
14.3.1 AGTC Company Details
-
14.3.2 AGTC Gene Therapy for Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Gene Therapy for Age-related Macular Degeneration
-
Figure Gene Therapy for Age-related Macular Degeneration Picture
-
Table Global Gene Therapy for Age-related Macular Degeneration Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Gene Therapy for Age-related Macular Degeneration Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Gene Therapy for Age-related Macular Degeneration Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Gene Therapy for Age-related Macular Degeneration Consumption by Country (2017-2022)
-
Figure United States Gene Therapy for Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)
-
Table Europe Gene Therapy for Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)
-
Figure China Gene Therapy for Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)
-
Figure Japan Gene Therapy for Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)
-
Figure India Gene Therapy for Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)
-
Figure South Korea Gene Therapy for Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)
-
Figure Global Gene Therapy for Age-related Macular Degeneration Consumption Forecast by Country (2022-2028)
-
Figure United States Gene Therapy for Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Gene Therapy for Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Gene Therapy for Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Gene Therapy for Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Gene Therapy for Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Gene Therapy for Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Subretinal Consumption and Growth Rate (2017-2022)
-
Figure Global Intravitreal Consumption and Growth Rate (2017-2022)
-
Figure Global Unspecified Consumption and Growth Rate (2017-2022)
-
Figure Global Monotherapy Consumption and Growth Rate (2017-2022)
-
Figure Global Combination Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Subretinal Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Intravitreal Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Unspecified Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Monotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Combination Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Gene Therapy for Age-related Macular Degeneration Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Gene Therapy for Age-related Macular Degeneration Export by Region (Top 5 Countries) (2017-2028)
-
Table REGENXBIO (Foundation Year, Company Profile and etc.)
-
Table REGENXBIO Gene Therapy for Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)
-
Table REGENXBIO Gene Therapy for Age-related Macular Degeneration Product and Service
-
Table RetroSense Therapeutics (Foundation Year, Company Profile and etc.)
-
Table RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)
-
Table RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Product and Service
-
Table AGTC (Foundation Year, Company Profile and etc.)
-
Table AGTC Gene Therapy for Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)
-
Table AGTC Gene Therapy for Age-related Macular Degeneration Product and Service
-
